Literature DB >> 30253067

Mouse Model for Human Vitiligo.

Rebecca L Riding1, Jillian M Richmond1, John E Harris1.   

Abstract

Vitiligo is an autoimmune skin disease in which the pigment-producing melanocytes are destroyed by autoreactive CD8+ T cells. As a result, patients develop disfiguring white spots on the skin. This article discusses the first mouse model of vitiligo that develops epidermal depigmentation, similar to disease in human patients. To achieve epidermal depigmentation, mice are genetically engineered to retain melanocytes in the skin epidermis. Induction of disease occurs by adoptive transfer of melanocyte-specific CD8+ T cells into recipient mice and the subsequent activation of these T cells using a viral vector. Depigmentation of the epidermis occurs within 5 to 7 weeks in a patchy pattern similar to patients with vitiligo. This article describes the methods of vitiligo induction, quantification of lesion progression and regression, processing of the skin for detailed analysis, and how to use this model to inform clinical studies.
© 2018 by John Wiley & Sons, Inc. © 2018 John Wiley & Sons, Inc.

Entities:  

Keywords:  CD8 T cells; autoimmunity; melanocyte; mice; vitiligo

Mesh:

Substances:

Year:  2018        PMID: 30253067      PMCID: PMC6340773          DOI: 10.1002/cpim.63

Source DB:  PubMed          Journal:  Curr Protoc Immunol        ISSN: 1934-3671


  45 in total

Review 1.  Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up.

Authors:  Ali Alikhan; Lesley M Felsten; Meaghan Daly; Vesna Petronic-Rosic
Journal:  J Am Acad Dermatol       Date:  2011-09       Impact factor: 11.527

2.  Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.

Authors:  Jasper G van den Boorn; Debby Konijnenberg; Trees A M Dellemijn; J P Wietze van der Veen; Jan D Bos; Cornelis J M Melief; Florry A Vyth-Dreese; Rosalie M Luiten
Journal:  J Invest Dermatol       Date:  2009-02-26       Impact factor: 8.551

3.  Fractionation of T and B cells using magnetic beads.

Authors:  Angela M Thornton
Journal:  Curr Protoc Immunol       Date:  2003-11

4.  CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice.

Authors:  Jillian M Richmond; Elizabeth Masterjohn; Ruiyin Chu; Jennifer Tedstone; Michele E Youd; John E Harris
Journal:  J Invest Dermatol       Date:  2017-01-23       Impact factor: 8.551

5.  Optimizing Vitiligo Management: Past, Present, and Future.

Authors:  John E Harris
Journal:  Dermatol Clin       Date:  2017-04       Impact factor: 3.478

6.  Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study.

Authors:  Liza Gill; Allison Zarbo; Prescilia Isedeh; Gordon Jacobsen; Henry W Lim; Iltefat Hamzavi
Journal:  J Am Acad Dermatol       Date:  2015-10-27       Impact factor: 11.527

7.  Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity.

Authors:  James P Strassner; Mehdi Rashighi; Maggi Ahmed Refat; Jillian M Richmond; John E Harris
Journal:  J Am Acad Dermatol       Date:  2017-03-01       Impact factor: 11.527

Review 8.  Modern vitiligo genetics sheds new light on an ancient disease.

Authors:  Richard A Spritz
Journal:  J Dermatol       Date:  2013-05       Impact factor: 4.005

9.  Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo.

Authors:  Jillian M Richmond; James P Strassner; Lucio Zapata; Madhuri Garg; Rebecca L Riding; Maggi A Refat; Xueli Fan; Vincent Azzolino; Andrea Tovar-Garza; Naoya Tsurushita; Amit G Pandya; J Yun Tso; John E Harris
Journal:  Sci Transl Med       Date:  2018-07-18       Impact factor: 17.956

10.  Vitiligo and the melanocyte reservoir.

Authors:  Rafael Falabella
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

View more
  10 in total

Review 1.  T-cell positioning by chemokines in autoimmune skin diseases.

Authors:  Jillian M Richmond; James P Strassner; Kingsley I Essien; John E Harris
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

Review 2.  The Role of Memory CD8+ T Cells in Vitiligo.

Authors:  Rebecca L Riding; John E Harris
Journal:  J Immunol       Date:  2019-07-01       Impact factor: 5.422

3.  Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.

Authors:  Nesrine Boukhedouni; Christina Martins; Anne-Sophie Darrigade; Claire Drullion; Jérôme Rambert; Christine Barrault; Julien Garnier; Clément Jacquemin; Denis Thiolat; Fabienne Lucchese; Franck Morel; Khaled Ezzedine; Alain Taieb; François-Xavier Bernard; Julien Seneschal; Katia Boniface
Journal:  JCI Insight       Date:  2020-06-04

4.  Anatomically distinct fibroblast subsets determine skin autoimmune patterns.

Authors:  Zijian Xu; Daoming Chen; Yucheng Hu; Kaiju Jiang; Huanwei Huang; Yingxue Du; Wenbo Wu; Jiawen Wang; Jianhua Sui; Wenhui Wang; Long Zhang; Shuli Li; Chunying Li; Yong Yang; Jianmin Chang; Ting Chen
Journal:  Nature       Date:  2021-12-15       Impact factor: 49.962

Review 5.  Mouse Models of Alopecia Areata: C3H/HeJ Mice Versus the Humanized AA Mouse Model.

Authors:  Amos Gilhar; Rimma Laufer Britva; Aviad Keren; Ralf Paus
Journal:  J Investig Dermatol Symp Proc       Date:  2020-11

6.  Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo.

Authors:  Jillian M Richmond; James P Strassner; Mehdi Rashighi; Priti Agarwal; Madhuri Garg; Kingsley I Essien; Lila S Pell; John E Harris
Journal:  J Invest Dermatol       Date:  2018-11-10       Impact factor: 8.551

Review 7.  Translational Research in Vitiligo.

Authors:  Erica L Katz; John E Harris
Journal:  Front Immunol       Date:  2021-03-02       Impact factor: 7.561

8.  Multimodal analyses of vitiligo skin identify tissue characteristics of stable disease.

Authors:  Jessica Shiu; Lihua Zhang; Griffin Lentsch; Jessica L Flesher; Suoqin Jin; Christopher Polleys; Seong Jin Jo; Craig Mizzoni; Pezhman Mobasher; Jasmine Kwan; Francisca Rius-Diaz; Bruce J Tromberg; Irene Georgakoudi; Qing Nie; Mihaela Balu; Anand K Ganesan
Journal:  JCI Insight       Date:  2022-07-08

9.  Type I interferon signaling limits viral vector priming of CD8+ T cells during initiation of vitiligo and melanoma immunotherapy.

Authors:  Rebecca L Riding; Jillian M Richmond; Keitaro Fukuda; John E Harris
Journal:  Pigment Cell Melanoma Res       Date:  2020-10-26       Impact factor: 4.159

10.  Transcriptome Analysis and Emerging Driver Identification of CD8+ T Cells in Patients with Vitiligo.

Authors:  Qiancheng Deng; Jingchao Wei; Puyu Zou; Yangfan Xiao; Zhuotong Zeng; Yaqian Shi; Yi Zhan; Huiming Zhang; Bingsi Tang; Qinghai Zeng; Rong Xiao
Journal:  Oxid Med Cell Longev       Date:  2019-11-26       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.